课题基金 / 基金详情

DIFFERENTIATION OF MEDULLARY THYROID CARCINOMA CELLS

DIFFERENTIATION OF MEDULLARY THYROID CARCINOMA CELLS
甲状腺髓样癌细胞的分化
批准号:
2894761
负责人:
BARRY D. NELKIN
金额:
$38.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-04-01 至 2001-03-31

项目摘要

项目成果

BARRY D. NELKIN的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自研究者的摘要)在
英文摘要
DESCRIPTION: (adapted from the investigator's abstract) The studies in this application seek to elucidate the control of neuroendocrine differentiation in normal calcitonin producing thyroid C-cells and their neoplastic counterpart, medullary thyroid carcinoma (MTC). Understanding this control could provide important insight for events in tumor development and progression. Medullary thyroid carcinoma is a good model for this study, since defined stages of progression which involve loss of neuroendocrine differentiation features, including capacity for calcitonin production, have been identified. We have developed an in vitro system to study steps of MTC differentiation and progression. MTC cells in culture can be differentiated with respect to many characteristics of normal C-cells, including increased calcitonin gene expression, either chemically or by ras or raf oncogene introduction. The current proposal will further characterize these findings, by cell biology, biochemistry, and molecular biology, concentrating on the molecular mechanisms regulating the induced differentiation. The studies proposed will be important not only for identifying the processes which may be involved in MTC progression, but also for defining the factors and pathways involved in neuroendocrine differentiation, and further elucidating the mechanisms of ras and raf oncogene function in cells. 1. Two cloned proteins, which bind specifically to the ras/raf responsive elements of the calcitonin gene, will be characterized for their function as transcription factors. The mechanisms of regulation which may allow these proteins, in MTC and other cell types, to mediate phenotypic responses to ras or raf (differentiation or transformation) will be examined. 2. The ret oncogene, which is activated by mutation in hereditary MTC, and in many cases of sporadic MTC, is silenced during raf-mediated differentiation of MTC cells in culture. The mechanisms of this silencing will be explored. The possibility will be tested that ret silencing is a necessary or sufficient step for MTC terminal differentiation. This could have important therapeutic implications in MTC. It will be determined if ret can be silenced in other cell types, and if other tyrosine kinases can be silenced by similar mechanisms. If other tyrosine kinases can be silenced, this could also provide a therapeutic target in several common cancers, in which overexpression of tyrosine kinases contributes to cancer growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EXPLOITATION OF RET INHIBITORS FOR TREATMENT OF THYROID CANCER
  • 批准号:
    7300571
  • 项目类别:
  • 资助金额:
    $29.54万
  • 财政年份:
    2007
  • 负责人:
    BARRY D. NELKIN
  • 依托单位:
The Role of CDK5 in Metastasis
  • 批准号:
    7798576
  • 项目类别:
  • 资助金额:
    $35.05万
  • 财政年份:
    2001
  • 负责人:
    BARRY D. NELKIN
  • 依托单位:
Ras/raf/rho in Lung Cancer Growth and Differentiation
  • 批准号:
    6633658
  • 项目类别:
  • 资助金额:
    $33.93万
  • 财政年份:
    2001
  • 负责人:
    BARRY D. NELKIN
  • 依托单位:
The Role of CDK5 in Metastasis
  • 批准号:
    7367520
  • 项目类别:
  • 资助金额:
    $35.05万
  • 财政年份:
    2001
  • 负责人:
    BARRY D. NELKIN
  • 依托单位:
海外基金